+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Idiopathic Pulmonary Fibrosis (IPF) - Market Insights, Epidemiology and Market Forecast - 2028

  • ID: 4564655
  • Drug Pipelines
  • 196 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Biogen Inc
  • Celgene Corporation
  • Galapagos NV
  • InterMune Inc.
  • LTT Bio-Pharma
  • MORE
‘Idiopathic Pulmonary Fibrosis (IPF) - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of IPF in the United States, Canada, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Idiopathic Pulmonary Fibrosis from 2017 to 2028 segmented by eight major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
  • Canada
Study Period: 2017-2028

Idiopathic Pulmonary Fibrosis (IPF) - Disease Understanding and Treatment Algorithm

The Idiopathic Pulmonary Fibrosis market report gives the thorough understanding of the Idiopathic Pulmonary Fibrosis by including details such as disease definition, staging, symptoms, pathophysiology, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for etiology in the US, Europe, and Japan.

Idiopathic Pulmonary Fibrosis (IPF) Epidemiology

The Idiopathic Pulmonary Fibrosis (IPF) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every eight major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent diagnosed cases, severity-specific prevalent cases and gender and age -specific prevalent cases) scenario of Idiopathic Pulmonary Fibrosis (IPF) in the G8 covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), Canada, and Japan from 2017-2028.

According to the publisher, total prevalent population of Idiopathic Pulmonary Fibrosis (IPF) in G8 markets was found to be 229,170 in 2017.

Idiopathic Pulmonary Fibrosis Drug Chapters

This segment of the IPF Drug report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs and biosimilars. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, and the latest news and press releases.

At present, therapeutic approach of IPF involves both non-pharmacological and pharmacological strategies. Non-pharmacological approach include supplemental oxygen therapy, pulmonary rehabilitation, mechanical ventilation and palliative care services. While the pharmacological treatment options include corticosteroids, immunosuppressive/cytotoxic agents (azathioprine, cyclophosphamide) and anti-fibrotic agents (e.g., colchicine or d-penicillamine) alone or in combination. At present two therapies have obtained approval for treatment of IPF that include antifibrotic drugs (Pirfenidone and Nintedanib). Detailed chapter for upcoming therapies like Thrombomodulin Alfa (Asahi Kasei Pharma Corporation), Pamrevlumab (FibroGen), KD025 (Kadmon Corporation, LLCs) etc. and other promising therapies such as CC-90001 (Celgene Corporation), LT1001 (LTT Bio-Pharma), BG00011 (Biogen Inc) etc. have also been covered in the report.

Idiopathic Pulmonary Fibrosis Market Outlook

The IPF market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, the market of Idiopathic Pulmonary Fibrosis in 8G was found to be USD 1644.4 million in 2017.

Idiopathic Pulmonary Fibrosis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Idiopathic Pulmonary Fibrosis Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Idiopathic Pulmonary Fibrosis Report Key Strengths
  • 10 Year Forecast
  • G8 Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Idiopathic Pulmonary Fibrosis Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving Idiopathic Pulmonary Fibrosis market
  • Organize sales and marketing efforts by identifying the best opportunities for Idiopathic Pulmonary Fibrosis market
  • To understand the future market competition in the Idiopathic Pulmonary Fibrosis market.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Biogen Inc
  • Celgene Corporation
  • Galapagos NV
  • InterMune Inc.
  • LTT Bio-Pharma
  • MORE
1. Key Insights

2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2028

3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. G8 Diagnosed Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.1.1. Diagnosed Prevalent cases of IPF in the United States
4.3.1.2. Diagnosed Prevalent Population of IPF by severity
4.3.1.3. Gender-Specific IPF Diagnosed Prevalence
4.3.1.4. Age-Specific IPF Diagnosed Prevalence
4.3.2. Canada
4.3.2.1. Diagnosed Prevalent cases of IPF in Canada
4.3.2.2. Diagnosed Prevalent Population of IPF by severity
4.3.2.3. Gender-Specific IPF Diagnosed Prevalence
4.3.2.4. Age-Specific IPF Diagnosed Prevalence
4.3.3. EU5
4.3.3.1. Diagnosed Prevalent Population of IPF in EU5
4.3.4. France
4.3.4.1. Diagnosed Prevalent Population of IPF
4.3.4.2. Diagnosed Prevalent Population of IPF by severity
4.3.4.3. Gender-Specific IPF Diagnosed Prevalence
4.3.4.4. Age-Specific IPF Diagnosed Prevalence
4.3.5. Germany
4.3.5.1. Diagnosed Prevalent Population of IPF
4.3.5.2. Diagnosed Prevalent Population of IPF by severity
4.3.5.3. Gender-Specific IPF Diagnosed Prevalence
4.3.5.4. Age-Specific IPF Diagnosed Prevalence
4.3.6. Italy
4.3.6.1. Diagnosed Prevalent Population of IPF
4.3.6.2. Diagnosed Prevalent Population of IPF by severity
4.3.6.3. Gender-Specific IPF Diagnosed Prevalence
4.3.6.4. Age-Specific IPF Diagnosed Prevalence
4.3.7. Spain
4.3.7.1. Diagnosed Prevalent Population of IPF
4.3.7.2. Diagnosed Prevalent Population of IPF by severity
4.3.7.3. Gender-Specific IPF Diagnosed Prevalence
4.3.7.4. Age-Specific IPF Diagnosed Prevalence
4.3.8. United Kingdom
4.3.8.1. Diagnosed Prevalent Population of IPF
4.3.8.2. Diagnosed Prevalent Population of IPF by severity
4.3.8.3. Gender-Specific IPF Diagnosed Prevalence
4.3.8.4. Age-Specific IPF Diagnosed Prevalence
4.3.9. Japan
4.3.9.1. Diagnosed Prevalent Population of IPF
4.3.9.2. Diagnosed Prevalent Population of IPF by severity
4.3.9.3. Gender-Specific IPF Diagnosed Prevalence
4.3.9.4. Age-Specific IPF Diagnosed Prevalence

5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)

6. Unmet needs

7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co.
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile

8. Emerging Therapies
8.1. Key Cross Competition
8.2. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
8.2.1. Drug Description
8.2.2. Product Profile
8.2.3. Clinical Development
8.2.4. Clinical Trials Information
8.2.5. Safety and Efficacy
8.3. GLPG1690: Galapagos NV
8.3.1. Drug Description
8.3.2. Product Profile
8.3.3. Regulatory Milestones
8.3.4. Other Development Activities
8.3.5. Clinical Development
8.3.6. Safety and Efficacy
List To be continued in report

9. Other Promising Candidates
9.1. CC-90001: Celgene Corporation
9.1.1. Drug Description
9.1.2. Product Profile
9.1.3. Clinical Development
9.1.4. Safety and Efficacy
9.2. LT-1001: LTT Bio-Pharma
9.2.1. Drug Description
9.2.2. Product Profile
9.2.3. Regulatory Milestones
9.2.4. Other Development Activities
9.2.5. Clinical Development
9.2.6. Safety and Efficacy
9.3. BG00011: Biogen Inc
9.3.1. Drug Description
9.3.2. Product Profile
9.3.3. Regulatory Milestones
9.3.4. Other Development Activities
9.3.5. Clinical Development
9.3.6. Clinical Trials Information
9.3.7. Safety and Efficacy
List To be continued in report

10. IPF: Market Analysis
10.1. Key Findings
10.2. Total Market Size of IPF in 8G
10.3. Therapy Based Market Size of IPF in 8G
10.4. Market Size of IPF by Country
10.4.1. United States Market Analysis
10.4.1.1. Market Size of IPF in the US
10.4.1.2. Therapy Based Market Size of IPF in the US
10.4.2. EU5 Market Outlook
10.4.3. Germany
10.4.3.1. Market Size of IPF in Germany
10.4.3.2. Therapy Based Market Size of IPF in Germany
10.4.4. France
10.4.4.1. Market Size of IPF in France
10.4.4.2. Therapy Based Market Size of IPF in France
10.4.5. Italy
10.4.5.1. Market Size of IPF in Italy
10.4.5.2. Therapy Based Market Size of IPF in Italy
10.4.6. United Kingdom
10.4.6.1. Market Size of IPF in the UK
10.4.6.2. Therapy Based Market Size of IPF in the UK
10.4.7. Spain
10.4.7.1. Market Size of IPF in Spain
10.4.7.2. Therapy Based Market Size of IPF in Spain
10.4.8. Japan: Market Analysis
10.4.8.1. Market Size of IPF in Japan
10.4.8.2. Therapy Based Market Size of IPF in Japan
10.4.9. Canada: market Analysis
10.4.9.1. Market Size of IPF in Japan
10.4.9.2. Therapy Based Market Size of IPF in Japan

11. Market Drivers of IPF

12. Market Barriers of IPF

13. Appendix
13.1. Report Methodology

14. Publisher Capabilities

15. Disclaimer

16. About the Publisher

List of Tables
Table 1: Expected 1-year probability of death in patients with idiopathic pulmonary fibrosis
Table 2: The GAP (Gender, Age, and Physiology) score
Table 3: The GAP index and staging system
Table 4: G8, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Table 5: The United States, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Table 6: The United States, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
Table 7: The United States, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Table 8: The United States, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Table 9: EU5, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Table 10: Germany, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Table 11: Germany, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
Table 12: Germany, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Table 13: Germany, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Table 14: France, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Table 15: France, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
Table 16: France, GENDER-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Table 17: France, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Table 18: Italy, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Table 19: Italy, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
Table 20: Italy, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Table 21: Italy, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Table 22: The United Kingdom, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Table 23: The United Kingdom, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
Table 24: The United Kingdom, GENDER-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Table 25: The United Kingdom, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Table 26: Spain, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Table 27: Spain, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
Table 28: Spain, GENDER-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Table 29: Spain, AGE-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Table 30: Japan, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Table 31: Japan, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
Table 32: Japan, GENDER-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Table 33: Japan, AGE-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Table 34: Canada, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Table 35: Canada, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
Table 36: Canada, GENDER-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Table 37: Canada, AGE-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Table 38: Key Cross Analysis of Emerging Therapies
Table 39: ART-123, Clinical Trial Description, 2019
Table 40: Pamrevlumab, Clinical Trial Description, 2019
Table 41: KD025, Clinical Trial Description, 2019
Table 42: PRM151, Clinical Trial Description, 2019
Table 43: GLPG1690, Clinical Trial Description, 2019
Table 44: CC90001, Clinical Trial Description, 2019
Table 45: LT-1001, Clinical Trial Description, 2019
Table 46: BG00011, Clinical Trial Description, 2019
Table 47: PBI4050, Clinical Trial Description, 2019
Table 49: Tipelukast, Clinical Trial Description, 2019
Table 50: TD-139, Clinical Trial Description, 2019
Table 51: VAY736, Clinical Trial Description, 2019
Table 52: TAS-115, Clinical Trial Description, 2019
Table 53: ND-L02-s0201, Clinical Trial Description, 2019
Table 54: Nalbuphine ER, Clinical Trial Description, 2019
Table 55: RVT-1601, Clinical Trial Description, 2019
Table 56: 8 Major Market Size of Idiopathic Pulmonary Fibrosis in USD Million (2017-2028)
Table 57: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in G8 in USD Million (2017-2028)
Table 58: Market Size of Idiopathic Pulmonary Fibrosis in the US, USD Million (2017-2028)
Table 59: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in the US in USD Million (2017-2028)
Table 60: Market Size of Idiopathic Pulmonary Fibrosis in Germany, USD Million (2017-2028)
Table 61: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Germany in USD Million (2017-2028)
Table 62: Market Size of Idiopathic Pulmonary Fibrosis in France, USD Million (2017-2028)
Table 63: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in France in USD Million (2017-2028)
Table 64: Market Size of Idiopathic Pulmonary Fibrosis in Italy, USD Million (2017-2028)
Table 65: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Italy in USD Million (2017-2028)
Table 66: Market Size of Idiopathic Pulmonary Fibrosis in the UK, USD Million (2017-2028)
Table 67: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in the UK in USD Million (2017-2028)
Table 68: Market Size of Idiopathic Pulmonary Fibrosis in Spain, USD Million (2017-2028)
Table 69: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Spain in USD Million (2017-2028)
Table 70: Market Size of Idiopathic Pulmonary Fibrosis in Japan, USD Million (2017-2028)
Table 71:Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Japan in USD Million (2017-2028)
Table 72: Market Size of Idiopathic Pulmonary Fibrosis in Canada, USD Million (2017-2028)
Table 73:Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Canada in USD Million (2017-2028)

List of Figures
Figure 1: Risk factors associated with IPF
Figure 2: IPF associated clubbing of the fingertips
Figure 3: Stages of the pathogenesis of IPF
Figure 4: A schematic representing the current model for the pathogenesis of IPF
Figure 5: Possible mechanisms of fibrogenesis in IPF
Figure 6: Chest radiograph of a patient with idiopathic pulmonary fibrosis showing bilateral lower lobe reticular opacities
Figure 7: Subpleural honeycombing in IPF diagnosed patients
Figure 8: Diagnostic algorithm for idiopathic pulmonary fibrosis (IPF). Patients with suspected IPF
Figure 9: G8, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Figure 10: The United States, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Figure 11: The United States, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
Figure 12: The United States, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Figure 13: The United States, AGE-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Figure 14: EU5, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Figure 15: Germany, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Figure 16: Germany, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
Figure 17: Germany, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Figure 18: Germany, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Figure 19: France, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Figure 20: France, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
Figure 21: France, GENDER-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Figure 22: France, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Figure 23: Italy, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Figure 24: Italy, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
Figure 25: Italy, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Figure 26: Italy, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Figure 27: The United Kingdom, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Figure 28: The United Kingdom, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
Figure 29: The United Kingdom, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Figure 30: The United Kingdom, AGE-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Figure 31: Spain, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Figure 32: Spain, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
Figure 33: Spain, GENDER-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Figure 34: Spain, AGE-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Figure 35: Japan, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Figure 36: Japan, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
Figure 37: Japan, GENDER-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Figure 38: Japan, AGE-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Figure 39: Canada, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Figure 40: Canada, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
Figure 41: Canada, GENDER-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Figure 42: Canada, AGE-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
Figure 43: Suggested Algorithm for IPF Treatment
Figure 44: Unmet Needs of IPF
Figure 45: 8 Major Market Size of Idiopathic Pulmonary Fibrosis in USD Million (2017-2028)
Figure 46: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in G8 in USD Million (2017-2028)
Figure 47: Market Size of Idiopathic Pulmonary Fibrosis in the US, USD Million (2017-2028)
Figure 48: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in the US in USD Million (2017-2028)
Figure 49: Market Size of Idiopathic Pulmonary Fibrosis in Germany, USD Million (2017-2028)
Figure 50: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Germany in USD Million (2017-2028)
Figure 51: Market Size of Idiopathic Pulmonary Fibrosis in France, USD Million (2017-2028)
Figure 52: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in France in USD Million (2017-2028)
Figure 53: Market Size of Idiopathic Pulmonary Fibrosis in Italy, USD Million (2017-2028)
Figure 54: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Italy in USD Million (2017-2028)
Figure 55: Market Size of Idiopathic Pulmonary Fibrosis in the UK, USD Million (2017-2028)
Figure 56: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in The UK in USD Million (2017-2028)
Figure 57: Market Size of Idiopathic Pulmonary Fibrosis in Spain, USD Million (2017-2028)
Figure 58: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Spain in USD Million (2017-2028)
Figure 59: Market Size of Idiopathic Pulmonary Fibrosis in Japan, USD Million (2017-2028)
Figure 60: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Japan in USD Million (2017-2028)
Figure 61: Market Size of Idiopathic Pulmonary Fibrosis in Canada, USD Million (2017-2028)
Figure 62: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Canada in USD Million (2017-2028)
Figure 63: Market Drivers of IPF
Figure 64: Market Barriers of IPF
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • InterMune Inc.
  • Boehringer Ingelheim Pharma GmbH & Co.
  • Asahi Kasei Pharma Corporation
  • Galapagos NV
  • Celgene Corporation
  • LTT Bio-Pharma
  • Biogen Inc
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4564655
Adroll
adroll